<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03288012</url>
  </required_header>
  <id_info>
    <org_study_id>NL60834.018.17</org_study_id>
    <nct_id>NCT03288012</nct_id>
  </id_info>
  <brief_title>Sickle Cell Disease: Targeting Alloantibody Formation Reduction; Risk Factors, and Genetics</brief_title>
  <acronym>STARRING</acronym>
  <official_title>Sickle Cell Disease: Targeting Alloantibody Formation Reduction; Risk Factors, and Genetics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanquin Research &amp; Blood Bank Divisions</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>HagaZiekenhuis</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Erasmus Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sanquin Research &amp; Blood Bank Divisions</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The focus of the study is the pathophysiological mechanism of allo-antibody formation after
      red blood cell transfusion in sickle cell disease patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main objectives of this study are to study the role of the innate and adaptive immune
      response in allo-antibody formation and furthermore to identify the genetic and time
      dependent clinical risk factors on alloimmunization in SCD patients.

      Subjects without allo-antibodies, receiving a red blood cell transfusion, will be included in
      this study. At 5 time points blood will be drawn from these subjects. (T0: Before
      transfusion, T1: 1 day after transfusion, T2: 1 week after transfusion, T3: 4 weeks after
      transfusion, T4: 6 months after transfusion).

      At each time point specific markers of the immune system will be measured.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 20, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The innate and adaptive immune response of patients with sickle cell disease that form allo-antibodies following erythrocyte transfusion, compared to patients that do not form alloantibodies following erythrocyte transfusion</measure>
    <time_frame>6 months</time_frame>
    <description>Multiple activating and regulatory markers of the innate and adaptive immune system will be measured at the indicated time points and compared between cases and controls</description>
  </primary_outcome>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Alloimmunization</condition>
  <condition>Sickle Cell Disease</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples for DNA analysis and analysis of immune system components involved in
      alloimmune reactions following erythrocyte transfusion
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Sickle cell disease population receiving care in the participating hospitals
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Sickle cell disease

          -  Receiving a red blood cell transfusion

        Exclusion Criteria:

          -  Previous positive screen for allo-antibodies

          -  &gt;25 red blood cell units in the past
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Academic Medical Center Amsterdam</name>
      <address>
        <city>Amsterdam-Zuidoost</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karin Fijnvandraat, PhD</last_name>
      <phone>+31 02 5123122</phone>
      <email>c.j.fijnvandraat@amc.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>HagaZiekenhuis</name>
      <address>
        <city>Den Haag</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean Louis Kerkhoffs, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Jean-Louis Kerkhoffs, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Radboudumc</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>S Schols, MD</last_name>
      <phone>0031243618800</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Erasmus MC</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marjon Cnossen, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Marjon Cnossen, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2017</study_first_submitted>
  <study_first_submitted_qc>September 15, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 19, 2017</study_first_posted>
  <last_update_submitted>March 14, 2018</last_update_submitted>
  <last_update_submitted_qc>March 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Isoantibodies</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

